Track Opiant Pharmaceuticals's net income ($-33M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2022
Trailing 12 months ending Sep 2022
Loading...
Loading...
As of the most recent data (September 2022), OPNT shows a net income of $-33M. That compares with $1.6M in the prior-year period — down 2231.8% year over year. That is below the Healthcare sector average of $16B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, OPNT's net income is now $-33M (was $1.6M) — a 2231.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Opiant Pharmaceuticals is outperforming or lagging.
The Healthcare sector average net income is about $16B. Opiant Pharmaceuticals is at $-33M, which is lower that average. That is roughly 100.2% below the sector mean. Use the comparison chart on this page to see how OPNT stacks up against individual peers as well.
Tracking OPNT's net income over time shows whether Opiant Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $-33M That compares with $1.6M in the prior-year period — down 2231.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this net income page, Stockcircle has Opiant Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-33M) with ownership activity and broader fundamentals.